LSTA
Price:
$3.095
Market Cap:
$25.98M
Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. The company was formerl...[Read more]
Industry
Biotechnology
IPO Date
1999-03-01
Stock Exchange
NASDAQ
Ticker
LSTA
According to Lisata Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -1.23. This represents a change of -0.67% compared to the average of -1.24 of the last 4 quarters.
The mean historical PE Ratio of Lisata Therapeutics, Inc. over the last ten years is -1.11. The current -1.23 PE Ratio has changed 10.93% with respect to the historical average. Over the past ten years (40 quarters), LSTA's PE Ratio was at its highest in in the June 2020 quarter at 0.89. The PE Ratio was at its lowest in in the December 2019 quarter at -20.18.
Average
-1.11
Median
-1.17
Minimum
-2.71
Maximum
1.44
Discovering the peaks and valleys of Lisata Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 337.57%
Maximum Annual PE Ratio = 1.44
Minimum Annual Increase = -354.49%
Minimum Annual PE Ratio = -2.71
Year | PE Ratio | Change |
---|---|---|
2023 | -1.06 | 337.57% |
2022 | -0.24 | -85.71% |
2021 | -1.69 | -37.63% |
2020 | -2.71 | 110.36% |
2019 | -1.29 | -39.57% |
2018 | -2.13 | -247.73% |
2017 | 1.44 | -354.49% |
2016 | -0.57 | -12.38% |
2015 | -0.65 | -71.22% |
2014 | -2.25 | -37.24% |
The current PE Ratio of Lisata Therapeutics, Inc. (LSTA) is less than than its 3-year, greater than its 5-year, and less than than its 10-year historical averages
3-year avg
-1.00
5-year avg
-1.40
10-year avg
-1.11
Lisata Therapeutics, Inc.’s PE Ratio is less than Lixte Biotechnology Holdings, Inc. (-1.18), less than Histogen Inc. (-0.01), less than Imunon, Inc. (-0.00), less than Kineta, Inc. (-0.36), greater than Rezolute, Inc. (-4.44), greater than Cyteir Therapeutics, Inc. (-9.12), greater than XOMA Corporation (-10.60), less than Protagenic Therapeutics, Inc. (-0.39), less than Tempest Therapeutics, Inc. (-0.62), greater than Pulmatrix, Inc. (-2.29), less than Onconova Therapeutics, Inc. (-0.08), greater than Catalyst Biosciences, Inc. (-28.21), less than Bio-Path Holdings, Inc. (-0.30), less than Moleculin Biotech, Inc. (-0.22), greater than Alpine Immune Sciences, Inc. (-112.94), less than AN2 Therapeutics, Inc. (-0.67), less than Ampio Pharmaceuticals, Inc. (-0.00), greater than Monte Rosa Therapeutics, Inc. (-4.84), greater than Candel Therapeutics, Inc. (-5.40),
Company | PE Ratio | Market cap |
---|---|---|
-1.18 | $4.70M | |
-0.01 | $85.44K | |
-0.00 | $11.82M | |
-0.36 | $7.05M | |
-4.44 | $255.53M | |
-9.12 | $108.71M | |
-10.60 | $301.64M | |
-0.39 | $3.34M | |
-0.62 | $37.39M | |
-2.29 | $22.14M | |
-0.08 | $20.90M | |
-28.21 | $19.42M | |
-0.30 | $4.48M | |
-0.22 | $5.81M | |
-112.94 | $4.46B | |
-0.67 | $40.64M | |
-0.00 | $2.95K | |
-4.84 | $433.13M | |
-5.40 | $391.38M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Lisata Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Lisata Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Lisata Therapeutics, Inc.'s PE Ratio?
How is the PE Ratio calculated for Lisata Therapeutics, Inc. (LSTA)?
What is the highest PE Ratio for Lisata Therapeutics, Inc. (LSTA)?
What is the 3-year average PE Ratio for Lisata Therapeutics, Inc. (LSTA)?
What is the 5-year average PE Ratio for Lisata Therapeutics, Inc. (LSTA)?
How does the current PE Ratio for Lisata Therapeutics, Inc. (LSTA) compare to its historical average?